Andrew Tsai
Stock Analyst at Jefferies
(3.80)
# 1,055
Out of 5,182 analysts
29
Total ratings
52%
Success rate
11.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DRUG Bright Minds Biosciences | Initiates: Buy | $145 | $88.99 | +62.94% | 1 | Apr 13, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $200 → $245 | $185.00 | +32.43% | 2 | Feb 3, 2026 | |
| DFTX Definium Therapeutics | Initiates: Buy | $30 | $21.27 | +41.04% | 1 | Jan 30, 2026 | |
| VTGN Vistagen Therapeutics | Downgrades: Hold | $15 → $0.9 | $0.60 | +50.85% | 3 | Dec 17, 2025 | |
| MRNA Moderna | Initiates: Hold | $30 | $47.14 | -36.36% | 1 | Dec 12, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $300 → $450 | $321.92 | +39.79% | 2 | Dec 9, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $32 | $30.31 | +5.58% | 1 | Nov 21, 2025 | |
| ANRO Alto Neuroscience | Maintains: Buy | $15 → $25 | $24.47 | +2.17% | 2 | Nov 12, 2025 | |
| BIIB Biogen | Initiates: Buy | $190 | $183.38 | +3.61% | 1 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $40 → $35 | $21.07 | +66.11% | 3 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $33.33 | -9.99% | 1 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $69.71 | +0.42% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $29 → $2.5 | $3.43 | -27.11% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $27 | $15.79 | +70.99% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $3.5 → $13 | $7.24 | +79.56% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $33.74 | +3.73% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $3 | $1.66 | +80.72% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $4.33 | +523.56% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $54.53 | -57.82% | 1 | Jun 1, 2020 |
Bright Minds Biosciences
Apr 13, 2026
Initiates: Buy
Price Target: $145
Current: $88.99
Upside: +62.94%
Axsome Therapeutics
Feb 3, 2026
Maintains: Buy
Price Target: $200 → $245
Current: $185.00
Upside: +32.43%
Definium Therapeutics
Jan 30, 2026
Initiates: Buy
Price Target: $30
Current: $21.27
Upside: +41.04%
Vistagen Therapeutics
Dec 17, 2025
Downgrades: Hold
Price Target: $15 → $0.9
Current: $0.60
Upside: +50.85%
Moderna
Dec 12, 2025
Initiates: Hold
Price Target: $30
Current: $47.14
Upside: -36.36%
Praxis Precision Medicines
Dec 9, 2025
Maintains: Buy
Price Target: $300 → $450
Current: $321.92
Upside: +39.79%
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $32
Current: $30.31
Upside: +5.58%
Alto Neuroscience
Nov 12, 2025
Maintains: Buy
Price Target: $15 → $25
Current: $24.47
Upside: +2.17%
Biogen
Sep 25, 2025
Initiates: Buy
Price Target: $190
Current: $183.38
Upside: +3.61%
Sarepta Therapeutics
Jul 24, 2025
Maintains: Buy
Price Target: $40 → $35
Current: $21.07
Upside: +66.11%
Jul 18, 2025
Initiates: Buy
Price Target: $30
Current: $33.33
Upside: -9.99%
Jul 14, 2025
Initiates: Buy
Price Target: $70
Current: $69.71
Upside: +0.42%
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $3.43
Upside: -27.11%
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $15.79
Upside: +70.99%
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $7.24
Upside: +79.56%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $33.74
Upside: +3.73%
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.66
Upside: +80.72%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $4.33
Upside: +523.56%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $54.53
Upside: -57.82%